A study from the Joint Asia Diabetes Evaluation shows that the age when a person is diagnosed with type 2 may have an effect on the complications that person later experiences. Interestingly, the study suggests a reason for the likelihood of more complications despite being younger is tied into the use of statins.
Based on a statistical analysis of almost 600,000 American Adults in three studies, the Centers for Disease Control estimates that 40 percent of all U.S. adults 20 years or older will develop type 2 diabetes in their lives. (The risk for men was estimated at 40.2 percent and for women, 39.6 percent.)For Hispanic men and women and non-Hispanic black women, the statistical risk is higher: more than 50 percent.
Chinese researchers found that type 2 diabetes patients taking metformin – one of the first lines of defense in the treatment of the disease - attained a better overall lipid profile compared with those who took glipizide.
A new wound-care dressing developed by a California firm has been shown to not only reduce the cost of treating wounds, but also to improve the outcomes of those treatments.
That’s good news for diabetics. According to statistics, about 15 percent of those with the disease develop chronic wounds – most often foot ulcers – that can result in amputation.
The was study, conducted at the Southwest Regional Wound Care Center in Lubbock, Texas. They found, Enluxtra Any Wound dressing developed by OSNovative Systems, Inc., reduced medical costs of chronic wound care by 30 percent. In part because it replaces many different products. Including primary foam, the gelling agent alginate, hydrogel dressings, hydro-conductive fiber, super-absorbent collagen, opaque dressing, hydrocolloid, gauze and combination dressings.
Any Wound dressing, crafted of FDA-approved polymers, is designed to sense and accommodate the different parts of the wound that need hydration or absorption, and a single dressing can remain in place for up to seven days.
An Italian-based pharmaceutical company with subsidiaries in New York has been granted orphan drug status for a new drug to treat neurotrophic keratitis, a rare degenerative corneal disease that impacts less than 1 in 5,000 people worldwide.
For most of us with diabetes, diabetes cure research can feel like it's moving at a glacial pace. If you're a mouse, it's probably pretty exciting, considering researchers are discovering new ways to cure you almost every day. But what progress is being made in curing this disease? Is anyone moving beyond the lab rats and into people living with diabetes? The good news is yes, and there are a lot of people working on finding a cure, and many of them have started or will be starting clinical research in humans soon.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.